Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John Michael Kelley, Ph.D.

Co-Author

This page shows the publications co-authored by John Kelley and Irving Kirsch.
Connection Strength

0.897
  1. Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus. Psychother Psychosom. 2018; 87(4):204-210.
    View in: PubMed
    Score: 0.191
  2. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med. 2009 Sep; 71(7):789-97.
    View in: PubMed
    Score: 0.104
  3. Patient-clinician brain concordance underlies causal dynamics in nonverbal communication and negative affective expressivity. Transl Psychiatry. 2022 01 28; 12(1):44.
    View in: PubMed
    Score: 0.061
  4. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain. 2021 09 01; 162(9):2428-2435.
    View in: PubMed
    Score: 0.060
  5. "Consensus on Placebo and Nocebo Effects Connects Science with Practice:" Reply to "Questioning the Consensus on Placebo and Nocebo Effects". Psychother Psychosom. 2021; 90(3):213-214.
    View in: PubMed
    Score: 0.058
  6. Dynamic brain-to-brain concordance and behavioral mirroring as a mechanism of the patient-clinician interaction. Sci Adv. 2020 10; 6(43).
    View in: PubMed
    Score: 0.056
  7. What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus. Psychother Psychosom. 2021; 90(1):49-56.
    View in: PubMed
    Score: 0.056
  8. European Headache Federation recommendations for placebo and nocebo terminology. J Headache Pain. 2020 Sep 25; 21(1):117.
    View in: PubMed
    Score: 0.056
  9. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. Trials. 2017 05 25; 18(1):234.
    View in: PubMed
    Score: 0.044
  10. Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. Brain Behav. 2015 Jan; 5(1):39-44.
    View in: PubMed
    Score: 0.037
  11. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014 Jan 08; 6(218):218ra5.
    View in: PubMed
    Score: 0.035
  12. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012; 7(10):e48135.
    View in: PubMed
    Score: 0.032
  13. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011 Jul 14; 365(2):119-26.
    View in: PubMed
    Score: 0.030
  14. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010 Dec 22; 5(12):e15591.
    View in: PubMed
    Score: 0.028
  15. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008 May 03; 336(7651):999-1003.
    View in: PubMed
    Score: 0.024
  16. Do "placebo responders" exist? Contemp Clin Trials. 2008 Jul; 29(4):587-95.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.